Literature DB >> 27308734

Contemporary Gleason grading and novel Grade Groups in clinical practice.

Cristina Magi-Galluzzi1, Rodolfo Montironi, Jonathan I Epstein.   

Abstract

PURPOSE OF REVIEW: The Gleason grading system provides important information for guiding prostate cancer patients' management and prognostication. The grading system underwent significant modifications over the past decade. In 2005 and more recently in 2014, the International Society of Urological Pathology (ISUP) held two consensus conferences to update prostate cancer grading. Recently, five prognostic grade groups have been proposed to be used in parallel to the Gleason grading system. The purpose of this review is to highlight the key changes in the Gleason grading system and the utility of the grade groups to better reflect biologic behavior for both patients and clinicians. RECENT
FINDINGS: At the 2014 ISUP consensus conference, prostate cancer Gleason grading was updated and a previously proposed concept of five prognostic grade groups, from 1 to 5 was supported. The Grade Groups, used in parallel to the modified Gleason grading system, translate Gleason scores in five distinct risk categories where Grade Group 1 is defined as Gleason score 6 or less, Grade Group 2 as Gleason score 3 + 4 = 7, Grade Group 3 as Gleason score 4 + 3 = 7, Grade Group 4 as Gleason score 4 + 4 = 8, and Grade Group 5 as Gleason score 9/10. This 5-tiered grade group system better reflects biologic behavior and guides clinical care. The Grade Groups have been endorsed by the ISUP and the World Health Organization. The performance of the Grade Groups has been examined in several recent studies.
SUMMARY: This review summarizes developments over the last year in the use of grade groups and outlines their value in clinical practice.

Entities:  

Mesh:

Year:  2016        PMID: 27308734     DOI: 10.1097/MOU.0000000000000320

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  5 in total

1.  Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness.

Authors:  Marco Prunotto; Rafael Fridman; R Daniel Bonfil; Wei Chen; Semir Vranic; Anjum Sohail; Dongping Shi; Hyejeong Jang; Hyeong-Reh Kim
Journal:  Cancer Cell Int       Date:  2021-09-21       Impact factor: 6.429

2.  Prostate Cancer Patients' Understanding of the Gleason Scoring System: Implications for Shared Decision-Making.

Authors:  Erin K Tagai; Suzanne M Miller; Alexander Kutikov; Michael A Diefenbach; Ronak A Gor; Tahseen Al-Saleem; David Y T Chen; Sara Fleszar; Gem Roy
Journal:  J Cancer Educ       Date:  2019-06       Impact factor: 2.037

Review 3.  Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.

Authors:  Amilcar Flores-Morales; Diego Iglesias-Gato
Journal:  Front Oncol       Date:  2017-11-07       Impact factor: 6.244

4.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Cristina Magi-Galluzzi; Sofia Cañete-Portillo; Alcides Chaux; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Magda Zanelli; Maria Paola Bonasoni; Loredana De Marco; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Maria Carolina Gelli; Alessandro Tafuni; Moira Ragazzi
Journal:  Cells       Date:  2021-11-14       Impact factor: 6.600

5.  Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.

Authors:  M C Cursano; V Conteduca; E Scarpi; G Gurioli; C Casadei; S Gargiulo; A Altavilla; C Lolli; B Vincenzi; G Tonini; D Santini; U De Giorgi
Journal:  Sci Rep       Date:  2022-05-05       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.